-
Novo Nordisk has once again raised its sales and operating profit expectations for 2023
On October 13th, Danish pharmaceutical company Novo Nordisk announced on its official website that based on a fixed exchange rate (CER), sales for the first nine months of 2023 increased by 33% year- ... -
The slimming elixir is on sale! Novo Nordisk raised its annual operating profit growth by at least 40%
On October 13th local time, the official website of Novo Nordisk (NVO.US) announced that based on a fixed exchange rate (CER), sales for the first nine months of 2023 increased by 33% year-on-year, a ... -
Novo Nordisk's European stock fell 6.5%
On August 7th, Southern Finance and Economics reported that Novo Nordisk's European stock fell 6.5%. Novo Nordisk's Q2 net profit fell short of expectations, increasing only 3% year-on-year, and lowe ... -
Novo Nordisk GLP-1 weight loss drug officially enters China, what is the pricing
On November 17th, Novo Nordisk announced that its glucagon like peptide-1 receptor agonist (GLP-1 RA) weekly formulation, semaglutide (trade name: Novo Nordisk), for long-term weight management, has ... -
Novo Nordisk's acquisition of Catalent has been approved for completion
Novo Nordisk announced on December 14th local time that all regulatory closing conditions related to the review of Novo Nordisk's acquisition of US contract pharmaceutical company Catalent have been ...